Safety and efficacy of ranolazine for the treatment of chronic angina pectoris

Clinical Medicine Insights: Therapeutics

Volumn 5, Issue , 2013, Pages 1-14

  Aldakkak, Mohammed ^a   Stowe, David F ^a,b,c   Camara, Amadou K S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Marquette University   (United States)

Author keywords

Chronic angina; Late Na+ current; Mitochondria; Ranolazine

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; DILTIAZEM; GLYCERYL TRINITRATE; PLACEBO; RANOLAZINE;

ANGINA PECTORIS; ASTHENIA; CALCIUM CELL LEVEL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; HEADACHE; HEART PROTECTION; HUMAN; LOW DRUG DOSE; NAUSEA; PATIENT PREFERENCE; PERCUTANEOUS CORONARY INTERVENTION; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84872691105     PISSN: 1179559X     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMT.S7824     Document Type: Review

References (60)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. Jan 3, 2012;125(1):188-97.
2. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. Jun 2006;27(11):1341-81.
3. Holubkov R, Laskey WK, Haviland A, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am. Heart J. Nov 2002;144(5):826-33.
4. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. May 19, 2004;43(10):1743-51.
5. Gilead S. Ranexa® (Ranolazine Extended-Release Tablets). http://www.Gilead.Com/Pdf/Ranexa_Pi.Pdf.Pdf. Accessed Jul 27, 2012.
6. Reddy BM, Weintraub HS, Schwartzbard AZ. Ranolazine: a new approach to treating an old problem. Tex Heart Inst J. 2010;37(6):641-7.
7. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469-91.
8. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. Jan 1, 1996;93(1):135-42.
9. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. Jan 21, 2004;291(3):309-16.
10. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and longterm survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. Apr 21, 2004;43(8):1375-82.
11. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. Jul 1992;20(1):131-8.
12. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol. Jul 1, 1999; 84(1):46-50.
13. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. Feb 1, 2005;95(3):311-6.
14. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. Aug 1, 2006;48(3):566-75.
15. Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol. Jul 1993;109(3):748-50.
16. Cheng JW. Ranolazine for the management of coronary artery disease. Clin Ther. Dec 2006;28(12):1996-2007.
17. McCormack JG, Halestrap AP, Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev. Apr 1990; 70(2):391-425.
18. Randle PJ. Fuel selection in animals. Biochem Soc Trans. Oct 1986;14(5): 799-806.
19. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. Aug 24, 2004;110(8):904-10.
20. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. Aug 2004;44(2):192-9.
21. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long- QT syndrome. J Pharmacol Exp Ther. Aug 2004;310(2):599-605.
22. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. May 2006;148(1):16-24.
23. + exchange inhibitor, inhibits the mitochondrial death pathway. Circulation. Nov 4, 2003;108(18):2275-81.
24. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. Nov 1992;71(5):1231-41.
25. Wu J, Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Physiol. Mar 1994; 266(3 Pt 2):H1034-46.
26. Ward CA, Giles WR. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol. May 1, 1997; 500(Pt 3):631-42.
27. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. Jul 2006;318(1):214-22.
28. 2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. Oct 2011;64(4):381-92.
29. Beyder A, Strege PR, Reyes S, et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation. Jun 5, 2012;125(22):2698-706.
30. Wyatt KM, Skene C, Veitch K, Hue L, McCormack JG. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol. Nov 9, 1995;50(10):1599-606.
31. 2+ overload and ROS release. Cardiovasc Res. Jan 15, 2008;77(2):406-15.
32. Chen Q, Hoppel CL, Lesnefsky EJ. Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria. J Pharmacol Exp Ther. Jan 2006;316(1):200-7.
33. Gadicherla AK, Stowe DF, Antholine WE, Yang M, Camara AK. Damage to mitochondrial complex I during cardiac ischemia reperfusion injury is reduced indirectly by anti-anginal drug ranolazine. Biochim Biophys Acta. Mar 2012;1817(3):419-29.
34. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. Jul 15, 1999;341(Pt 2):233-49.
35. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. Cardiovasc Res. Feb 15, 2004;61(3):372-85.
36. Nayler WG. The role of calcium in the ischemic myocardium. Am J Pathol. Feb 1981;102(2):262-70.
37. Reuter H, Schwinger RH. Calcium handling in human heart failure-abnormalities and target for therapy. Wien Med Wochenschr. Jul 2012;162(13-4): 297-301.
38. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. Aug 1994;28(8):1231-7.
39. Hwang H, Arcidi JM Jr, Hale SL, et al. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation. Sep 15, 2009;120(Suppl 11):S16-21.
40. Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. Nov 2008;295(5):H2149-55.
41. Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail. Dec 2002;8(6):416-22.
42. Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. Jul 2008;45(1):32-43.
43. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. May 2006;17 Suppl 1:S169-77.
44. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. Oct 1994;8(5):741-7.
45. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. Dec 2008;19(12):1289-93.
46. Lovelock JD, Monasky MM, Jeong EM, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. Mar 16, 2012;110(6):841-50.
47. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST- elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. Apr 25, 2007;297(16):1775-83.
48. Pelliccia F, Pasceri V, Marazzi G, Rosano G, Greco C, Gaudio C. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. Am Heart J. Jun 2012; 163(6):1019-23.
49. Phelps CE, Buysman EK, Gomez Rey G. Costs and clinical outcomes associated with use of ranolazine for treatment of angina. Clin Ther. Jun 2012;34(6):1395-407.
50. Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J Cardiovasc Pharmacol Ther. Sep 2004;9 Suppl 1:S47-64.
51. Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol. Jul 2005;45(7):802-9.
52. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther. Apr 2010;27(4):193-201.
53. Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB. Ranolazine (RS- 43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol. 1990;38(2):111-4.
54. Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation. Aug 1994;90(2):726-34.
55. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation. Mar 1, 1995;91(5): 1368-74.
56. Pratt CM, McMahon RP, Goldstein S, et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). Am J Cardiol. Jun 15, 1996;77(15):1302-9.
57. Management of Stable Angina. A National Clinical Guideline. http://www.Guideline.Gov/Content.Aspx?Id=34825&Search=Chronic+Angina. Accessed Aug 6, 2012.
58. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. Oct 9, 2007;116(15):1647-52.
59. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. Apr 21, 2009;119(15):2032-9.
60. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. Nov 19, 2012. [Epub ahead of print.]